A Post-Marketing Commitment (PMC) study comparing weight-based (WB) dosing to a fixed regimen of Plerixafor in combination with granulocyte colony stimulating factor (G-CSF) in patients with non-Hodgkin's lymphoma (NHL)

Trial Profile

A Post-Marketing Commitment (PMC) study comparing weight-based (WB) dosing to a fixed regimen of Plerixafor in combination with granulocyte colony stimulating factor (G-CSF) in patients with non-Hodgkin's lymphoma (NHL)

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs Plerixafor (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 22 Apr 2016 New trial record
    • 12 Mar 2016 Results presented at the 117th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top